IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis https://www.accessnewswire.com/news...ma-trial-advances-toward-completion-a-1172698
